NCT04141241View on ClinicalTrials.gov

Phase 2a Study to Evaluate the Safety and Efficacy of PH100 Tablet in T2DM Patients With Recent Cardiovascular

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 4, 2016

Primary Completion Date

May 4, 2018

Study Completion Date

May 4, 2018

Conditions
Type 2 Diabetes Mellitus With Circulatory Complciation
Interventions
DRUG

Ecklonia cava Phlorotannin

Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.

All Listed Sponsors
lead

Bota Bio Co., Ltd.

INDUSTRY

NCT04141241 - Phase 2a Study to Evaluate the Safety and Efficacy of PH100 Tablet in T2DM Patients With Recent Cardiovascular | Biotech Hunter | Biotech Hunter